Drugs / Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06632912 | Nov 2025 → Jul 2032 expected | carcinoma, human papilloma virus infection | National Vaccine and Serum Institute, China | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06632912 ↗ |
| Modality | Vaccine | “experimental vaccine” NCT06632912 ↗ |
| Route | Intramuscular | “injected into the deltoid muscle of the upper arm” NCT06632912 ↗ |